 Skye Bioscience Inc OTCQB:SKYE said it has submitted an Investigational New Drug application IND to the US Food and Drug Administration FDA for its SBI-100 Ophthalmic Emulsion SBI-100 OE, which it is developing for the treatment of glaucoma. Once opened, the IND will allow Skye to conduct clinical trials in the US, the pharmaceutical company said. 